



Exploring heterometallic bridged Pt(II)-Zn(II) complexes as potential antitumor agents

Tanja V. Soldatović^{a,*}, Biljana Šmit^b, Emina M. Mrkalić^b, Sanja Lj. Matić^b, Ratomir M. Jelić^c, Marina Ćendić Serafinović^d, Nevenka Gligorijević^e, Milena Čavić^e, Sandra Arandelović^e, Sanja Grgurić-Šipka^{f,*}

^a Department of Natural-Mathematical Sciences, State University of Novi Pazar, Vuka Karadžića bb, Novi Pazar 36300, Serbia

^b Department of Science, Institute for Information Technologies, University of Kragujevac, Jovana Cvijića bb, Kragujevac 34000, Serbia

^c Faculty of Medical Sciences, Department of Pharmacy, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia

^d Faculty of Science, Department of Chemistry, University of Kragujevac, Radoja Domanovića 12, Kragujevac 34000, Serbia

^e Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, Serbia

^f Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, Belgrade 11000, Serbia

ARTICLE INFO

Keywords:

Heterometallic complexes
Structure-reactivity correlation
Antitumor agents

ABSTRACT

The four novel complexes [*cis*-PtCl(NH₃)₂(μ-4,4'-bipyridyl)ZnCl(terpy)](ClO₄)₂ (**C1**), [*trans*-PtCl(NH₃)₂(μ-4,4'-bipyridyl)ZnCl(terpy)](ClO₄)₂ (**C2**), [*cis*-PtCl(NH₃)₂(μ-pyrazine)ZnCl(terpy)](ClO₄)₂ (**C3**) and [*trans*-PtCl(NH₃)₂(μ-pyrazine)ZnCl(terpy)](ClO₄)₂ (**C4**) (where terpy = 2,2':6',2''-terpyridine) were synthesized and characterized. Acid–base titrations and concentration dependent kinetic measurements for the reactions with biologically relevant ligands such as guanosine-5'-monophosphate (5'-GMP), inosine-5'-monophosphate (5'-IMP) and glutathione (GSH), were studied at pH 7.4 and 37 °C. The binding of the heterometallic bridged *cis*- or *trans*-Pt(II)-Zn(II) complexes to calf thymus DNA (CT-DNA) was studied by UV absorption and fluorescence emission spectroscopy and molecular docking. The results indicated that the complexes bind strongly to DNA, through groove binding, hydrogen bonds, and hydrophobic or electrostatic interaction. The possible *in vitro* DNA protective effect of *cis*- and *trans*-Pt-L-Zn complexes has shown that **C3** had significant dose-dependent DNA-protective effect and the same ability to inhibit peroxy as well as hydroxyl radicals. Antiproliferative effect of the complexes, mRNA expression of apoptosis and repair-related genes after treatment in cancer cells indicated that newly synthesized **C2** exhibited highly selective cytotoxicity toward colon carcinoma HCT116 cells. Only treatment with *trans* analog **C2** induced effect similar to the typical DNA damaging agent such as cisplatin, characterized by p53 mediated cell response, cell cycle arrest and certain induction of apoptotic related genes. Both *cis*- and *trans*-isomers **C1** and **C2** showed potency to elicit expression of PARP1 mRNA and *in vitro* DNA binding.

Abbreviations: terpy, 2,2':6',2''-terpyridine; CDDP, *cis*-diamminedichloridoplatinum(II), *cis*-[PtCl₂(NH₃)₂]; 5'-GMP, guanosine-5'-monophosphate; 5'-IMP, inosine-5'-monophosphate; GSH, glutathione; DMF, dimethylformamide; ESI, electrospray ionization; CT-DNA, calf thymus deoxyribonucleic acid; B-DNA, right-handed double helix; cDNA, complementary DNA; EB, ethidium bromide; MTT, 3-(4,5-dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide; A549, human lung adenocarcinoma cells; HCT116, human adenocarcinoma colon cells; LS-174, human caucasian colon adenocarcinoma; MDA-MB-231, human breast carcinoma cell; MRC-5, non-tumor fibroblast cell line; IC₅₀, inhibitor concentration; DDR, DNA damage response; DMSO, dimethyl sulfoxide; RNaseA, Ribonuclease A from bovine pancreas; AZD2461, 4-[[4-Fluoro-3-[(4-methoxy-1-piperidinyl)carbonyl]phenyl]methyl]-1(2H)-phthalazinone; SDS, sodium dodecyl sulfate; PI, propidium iodide; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; PBS, phosphate-buffered saline; D₂O, deuterium oxide; TSP, trimethylsilylpropionic acid; DFT, density functional theory; AAPH, 2-methylpropionamide dihydrochloride; qRT-PCR, quantitative real-time polymerase chain reaction; Bax, bcl-2-like protein 4; Bcl2, B-cell lymphoma 2; XRCC2, X-ray repair cross complementing 2; ERCC1, endonuclease non-catalytic subunit; TP53, *homo sapiens* tumor protein p53; PARP1, poly(ADP-ribose) polymerase; H2AX, H2A histone family member X; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

* Corresponding authors.

E-mail addresses: tsoldatovic@np.ac.rs (T.V. Soldatović), sanjag@chem.bg.ac.rs (S. Grgurić-Šipka).

<https://doi.org/10.1016/j.jinorgbio.2022.112100>

Received 19 October 2022; Received in revised form 3 December 2022; Accepted 10 December 2022

Available online 14 December 2022

0162-0134/© 2022 Elsevier Inc. All rights reserved.